<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478035</url>
  </required_header>
  <id_info>
    <org_study_id>INFSNC1</org_study_id>
    <nct_id>NCT01478035</nct_id>
  </id_info>
  <brief_title>Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.</brief_title>
  <official_title>Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M. Carmen Cabellos Minguez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Juan Canalejo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Mutua de Terrassa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen Macarena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of the prophylaxis with phenytoin in the prevention of seizures in
      patients with pneumococcal meningitis. Hypothesis: Administration of prophylactic phenytoin
      will reduce the incidence of seizures in patients with pneumococcal meningitis older than 50
      yrs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Bacterial meningitis has still a high morbi-mortality despite the global
      improvement in therapy.

      Among complications, the presence of seizures may contribute to increase the morbi-mortality.
      Prophylactic phenytoin is used in clinical practice in high risk patients but this use is
      variable because there are not controlled clinical trials demonstrating efficacy along with
      antibiotics and corticosteorids. Pneumococcal episodes are associated to a higher number of
      seizures and a higher mortality especially in elderly patients.

      Objectives: To evaluate the efficacy of the prophylaxis with phenytoin in the prevention of
      seizures in patients with pneumococcal meningitis. Hypothesis: Administration of prophylactic
      phenytoin will reduce the incidence of seizures in patients with pneumococcal meningitis
      older than 50 yrs.

      Methodology: Multicentre, randomized, double blind placebo controlled clinical trial.
      Patients will be included mostly from hospitals from REIPI and CAIBER and randomly assigned
      to receive phenytoin or placebo.

      Sample size has been estimated in 61 patients per group. Antibiotic therapy and ICP
      prophylaxis will be standardized in all centres. Phenytoin administration will be maintained
      during antibiotic therapy. End point will be incidence of seizures during hospital stay and
      overall mortality will be a secondary end-point. Followup visits at 1 and 3 month will be
      performed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of seizures (clinical) after initiation of phenytoin /placebo prophylaxis during the 10 days of antibiotic therapy</measure>
    <time_frame>10 days</time_frame>
    <description>Presence of seizures (clinical) after initiation of phenytoin /placebo prophylaxis during the 10 days of antibiotic therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for anticonvulsivant therapy at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Need for anticonvulsivant therapy at 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Seizures</condition>
  <condition>Pneumococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>phenytoin prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with suspected or proven pneumococcal meningitis are allocated to receive phenytoin prophylaxis or placebo to avoid seizures during the 10 days of antibiotic therapy starting after the antibiotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo vials and pills labeled as phenytoin prophylaxis vials and pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenytoin</intervention_name>
    <description>Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.</description>
    <arm_group_label>phenytoin prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients &gt; or = 50 years old.

        Diagnosed of pneumococcal meningitis due to clinical characteristics plus a positive CSF
        Gram stain and/or a detection of pneumococcal antigen or PCR

        or

        Suspected pneumococcal meningitis since it is an episode related to otitis, pneumonia,
        sinusitis or pericranial fistula or in patients with known risk factors such as myeloma or
        splenectomy.

        Exclusion Criteria:

        To have seizures prior to arrive to the hospital or the inclusion in the study.

        Pregnancy or breastfeeding.

        To have conduction abnormalities in ECG.

        History of allergy or intolerance to phenytoin.

        Patients with meningitis as a complication of neurosurgical procedures.

        Epileptic patients taking usually anticonvulsivants.

        Refusal by the patient or family to participate and/or to sign the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Carmen Cabellos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M. Carmen Cabellos, MD</last_name>
    <phone>+34932607625</phone>
    <email>ccabellos@bellvitgehospital.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Cabellos</last_name>
      <phone>34932607625</phone>
      <email>ccabellos@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>M. Carmen Cabellos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canalejo</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efren Sanchez</last_name>
      <email>Efren.Sanchez.Vidal@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Efren Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacio Institut per la Recerca de l'hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Pomar</last_name>
      <email>VPomar@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Virginia Pomar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Mejias</last_name>
      <email>MEJ-MEJIAS@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Enrique Mejias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>M. Carmen Cabellos Minguez</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Phenytoin prophylaxis</keyword>
  <keyword>Pneumococcal meningitis</keyword>
  <keyword>Randomized</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Double blind</keyword>
  <keyword>Patient 50 years or older</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Pneumococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenytoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

